Viking Therapeutics Stock Gets RS Rating Upgrade

Group 1 - Viking Therapeutics (VKTX) stock received an upgrade in its Relative Strength (RS) Rating from 61 to 72, indicating a positive trend but still below the preferred benchmark of 80 or higher [1] - The stock has reclaimed its 50-day moving average in the last three trading days, suggesting potential for further recovery [1] - The company reported 0% growth in earnings per share (EPS) and sales in the last quarter, indicating stagnation in financial performance [1] Group 2 - Viking Therapeutics ranks No. 312 among its peers in the Medical-Biomed/Biotech industry group, highlighting its relative position within the sector [1] - Other highly rated stocks in the same industry include Kiniksa Pharmaceuticals (KNSA), Aurinia Pharmaceuticals (AUPH), and Amicus Therapeutics (FOLD) [1]